Organic compounds to treat hepatitis B virus

Patent metadata

Field	Value
Publication number	US-10519446-B2
Application number	US-201415025852-A
Country	US
Kind code	B2
Filing date	Sep 30, 2014
Priority date	Oct 4, 2013
Publication date	Dec 31, 2019
Grant date	Dec 31, 2019

Abstract

The disclosure relates to compositions comprising a HBV RNAi agent. In some embodiments, the HBV RNAi agent comprises a sense and an anti-sense strand, each strand being an 18-mer and the strands together forming a blunt-ended duplex, wherein the 3′ end of at least one strand terminates in a phosphate or modified internucleoside linker and further comprises, in 5′ to 3′ order: a spacer; a second phosphate or modified internucleoside linker; and a 3′ end cap. In some embodiments, the 3′ end of both the sense and anti-sense strand further comprise, in 5′ to 3′ order: a spacer; a second phosphate or modified internucleoside linker; and a 3′ end cap. The two strands can have the same or different spacers, phosphates or modified internucleoside linkers, and/or 3′ end caps. The strands can be ribonucleotides, or, optionally, one or more nucleotide can be modified or substituted. Optionally, at least one nucleotide comprises a modified internucleoside linker. Optionally, the RNAi agent can be modified on one or both 5′ end. Optionally, the sense strand can comprise a 5′ end cap which reduces the amount of the RNA interference mediated by this strand. Optionally, the RNAi agent is attached to a ligand. This format can be used to devise RNAi agents to a variety of different targets and sequences. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference. The disclosure also pertains to methods of treating, ameliorating and preventing HBV in a patient involving the step of administering to the patient a therapeutic amount of a HBV RNAi agent.

First claim

The invention claimed is:

1. A composition comprising a HBV RNAi agent comprising a first and a second strand, wherein a nucleotide sequence of the first and/or second strand is selected from the group consisting of:
SEQ ID NOS: 138-157 and SEQ ID NOS: 217-220, wherein at least one nucleotide is a modified nucleotide or is substituted, the at least one modified nucleotide being selected from the group consisting of 2′ alkoxyribonucleotide, 2′ alkoxyalkoxy ribonucleotide, 2′-fluoro ribonucleotide, 2′-OMe, 2′-MOE and 2′-H,
wherein a 3′ end of at least one of the first strand and the second strand terminates in one of a phosphate or modified internucleoside linker, and further comprises, in 5′ to 3′ order, a spacer and a 3′ end cap,
the 3′ end cap being selected from the group consisting of: X027, X038, X050, X051, X052, X058, X059, X060, X061, X062, X063, X064, X065, X066, X067, X068, X069, X097, X098, X109, X110, X111, X112, X113, X1009, X1010, X1011, X1012, X1013, X1015, X1016, X1017, X1018, X1019, X1020, X1021, X1022, X1024, X1025, X1026, X1027, X1028, X1047, X1048, X1049, X1062, X1063, and X1064.

2. The composition of claim 1 , wherein the HBV RNAi agent is blunt-ended.

3. The composition of claim 1 , wherein the first and second strands are 18-mers and together form a blunt-ended duplex.

4. The composition of claim 1 , wherein the spacer is ribitol.

5. The composition of claim 1 , wherein the spacer is selected from the group consisting of a ribitol, 2′-deoxyribitol, 2′-methoxyethoxy ribitol (ribitol with 2′-MOE), C3, C4, C5, C6, and 4-methoxybutane-1,3-diol.

6. The composition of claim 1 , wherein the modified internucleoside linker is selected from the group consisting of phosphorothioate, phosphorodithioate, phosphoramidate, boranophosphonoate, an amide linker, and a compound of formula (I), wherein R 3 is selected from the group consisting of O − , S − , NH 2 , BH 3 , CH 3 , C 1-6 alkyl, C 6-10 aryl, C 1-6 alkoxy and C 6-10 aryl-oxy, wherein C 1-6 alkyl and C 6-10 aryl are unsubstituted or optionally independently substituted with 1 to 3 groups independently selected from the group consisting of halo, hydroxyl and NH 2 ; and R 4 is selected from the group consisting of O, S, NH, and CH 2 .

7. The composition of claim 1 , wherein one or more nucleotides is modified or is substituted with DNA, a peptide nucleic acid (PNA), locked nucleic acid (LNA), morpholino nucleotide, threose nucleic acid (TNA), glycol nucleic acid (GNA), arabinose nucleic acid (ANA), 2″-fluoroarabinose nucleic acid (FANA), cyclohexene nucleic acid (CeNA), anhydrohexitol nucleic acid (HNA), and/or unlocked nucleic acid (UNA).

8. The composition of claim 1 , wherein the RNAi agent can be modified on a 5′ end of at least one of the first strand and the second strand.

9. The composition of claim 1 , wherein the sense strand comprises a 5′ end cap which reduces an amount of the RNA interference mediated by the sense strand.

10. The composition of claim 1 , wherein the sense strand comprises a 5′ end cap selected from the group consisting of: a nucleotide lacking a 5′ phosphate or 5′-OH; a nucleotide lacking a 5′ phosphate or a 5′-OH and also comprising a 2-OMe or 2′-MOE modification; 5′-deoxy-2′-O-methyl modification; 5′-OME-dT; ddT; and 5′-OTr-dT.

11. The composition of claim 1 , wherein said at least one modified nucleotide is 2′-OMe.

12. The composition of claim 1 , wherein the 3′ end cap comprises X058.

13. The composition of claim 1 , wherein the spacer comprises ribitol and the 3′ end cap comprises X058.

14. A method of treating or ameliorating HBV in a patient, comprising the step of administering to the patient a therapeutically effective amount of a composition of claim 1 .

Assignees

• Novartis Ag
• Baryza Jeremy Lee
• Blommers Marcel
• Fernandez Cesar
• Geno Erin
• Gossert Alvar
• Greenidge Paulette
• Huesken Dieter
• Hunziker Juerg
• Natt Francois Jean Charles
• Patnaik Anup
• Patterson Andrew
• Rondeau Jean Michel Rene
• Weiler Jan
• Zhu Meicheng
• Holdorf Meghan

Inventors

• Baryza Jeremy Lee
• Blommers Marcel
• Fernandez Cesar
• Geno Erin
• Gossert Alvar
• Greenidge Paulette
• Huesken Dieter
• Hunziker Juerg
• Natt Francois Jean-Charles
• Patnaik Anup
• Patterson Andrew
• Rondeau Jean-Michel Rene
• Weiler Jan
• Zhu Meicheng
• Holdorf Meghan

Classifications

• A61P31/20

  for DNA viruses · CPC title

• C12N2310/332

  Abasic residue · CPC title

• C12N2310/317

  with an inverted bond, e.g. a cap structure · CPC title

• C12N2310/321

  2'-O-R Modification · CPC title

• C12N15/1131 Primary

  against viruses · CPC title